Growth Differentiation Factor-15 Level and Tissue Doppler Echocardiography as a Tool in Identification of Cardiac Effects in the Children with Type 1 Diabetes Mellitus

Abstract

Objective The aim of this study was to evaluate the importance of growth-differentiation factor-15 level and tissue Doppler imaging in the detection of cardiomyopathy in children who have type 1 diabetes mellitus.

Materials and Methods Thirty-eight patients (11 males and 27 females) with type 1 diabetes mellitus were included in this study. The control group consisted of 40 age- and gender-matched healthy volunteers. All children underwent a detailed echocardiography, which contained an m-mode, pulse Doppler and tissue Doppler imaging; and growth-differentiation factor-15 level was measured.

Results In this study, there were significant differences between diastolic function parameters of the heart. The mitral isovolumic contraction time, contraction time, and isovolumic relaxation time values were different in the patients than in the controls (p<0.01, p<0.01, p<0.01, respectively). Also, the tricuspid isovolumic contraction time, contraction time, and isovolumic relaxation time values were different in the patients than in the controls (p<0.01, p=0.01, p<0.01, respectively). No statistically significant difference was found between the other M-mode parameters. Mean plasma growth-differentiation factor-15 level was significantly higher in patients than in healthy controls (p<0.01).

Conclusion The follow-up of children with type 1 diabetes mellitus in terms of cardiomyopathy and the use of tissue Doppler imaging and growth differentiation factor-15 levels may be useful.

Key words

tissue doppler imaging - growth differentiation factor-15 - type 1 diabetes mellitus - cardiac disfunction

Publication History

Received: 05 December 2018
Received: 27 June 2019

Accepted: 23 July 2019

Article published online:
19 August 2019

• References

• 1 Norris AW, Wolfsdorf JI, Brown RS. Diabetes Mellitus Clinical Pediatric Endocrinology 5^th Edition, Massachusetts (USA). Blackwell Publishing Ltd; 2005: 436-491
• 2 Herman WH, Braffett BH, Kuo S. et al. What are the clinical, quality-of-life, and cost consequences of 30 years of excellent vs. poor glycemic control in type 1 diabetes?. J Diabetes Complications 2018; 32: 911-915
• 3 De-Paula CR, Magalhães GS, Jentzsch NS. et al. Echocardiographic assessment of ventricular function in young patients with asthma. Arq Bras Cardiol 2018; 110: 231-239
• 4 Chinali M, Esposito C, Grutter G. et al. Cardiac dysfunction in children and young adults with heart transplantation: a comprehensive echocardiography study. J Heart Lung Transplant 2017; 36: 559-566
• 5 Ago T, Sadoshima J. GDF15, a cardioprotective TGF-beta superfamily protein. Circ Res 2006; 98: 294-297
• 6 Dinh W, Futh R, Lankisch M. Growth-differentiation factor-15: a novel biomarker in patients with diastolic dysfunction?. Arq Bras Cardiol 2011; 97: 65-75
• 7 Craig ME, Jefferies C, Dabelea D. et al. International Society for Pediatric and Adolescent Diabetes. ISPAD Clinical Practice Consensus Guidelines 2014. Definition, epidemiology, and classification of diabetes in children and adolescents. Pediatr Diabetes 2014; 20: 4-17
• 8 Neyzi O, Bundak R, Gökçay G. et al. Reference values for weight, height, head circumference, and body mass index in Turkish children. J Clin Res Pediatr Endocrinol 2015; 7: 280-293
• 9 Lang RM, Bierig M, Devereux RB. et al. Recommendations for chamber quantification. Eur J Echocardiogr 2006; 7: 79-108
• 10 Cheitlin MD, Armstrong WF, Aurigemma GP. et al. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). J Am Coll Cardiol 2003; 42: 954-970
• 11 Rubler S, Dlugash J, Yuceoglu YZ. et al. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972; 30: 595-602
• 12 Remuzzi A, Cornolti R, Bianchi R. et al. Regression of diabetic complications by islet transplantation in the rat. Diabetologia 2009; 52: 2653-2661
• 13 Maya L, Villarreal FJ. Diagnostic approaches for diabetic cardiomyopathy and myocardial fibrosis. J Mol Cell Cardiol 2010; 48: 524-529
• 14 Brunvand L, Fugelseth D, Stensaeth KH. et al. Early reduced myocardial diastolic function in children and adolescents with type 1 diabetes mellitus a population-based study. BMC Cardiovasc Disord 2016; 16: 103
• 15 Raev DC. Which left ventricular function is impaired earlier in the evolution of diabetic cardiomyopathy? An echocardiographic study of young type 1 diabetic patients. Diabetes Care 1994; 17: 633-639
• 16 Galderisi M. Diastolic dysfunction and diabetic cardiomyopathy: evaluation by Doppler echocardiography. J Am Coll Cardiol 2006; 48: 1548-1551
• 17 Danzmann L, Bodanese LC, Köhler I. et al. Left atrioventricular remodeling in the assessment of the left ventricle diastolic function in patients with heart failure: a review of the currently studied echocardiographic variables. Cardiovasc Ultrasound 2008; 6: 56
• 18 Karamitsos TD, Karvounis HI, Didangelos TP. et al. Aortic elastic properties are related to left ventricular diastolic function in patients with type 1 diabetes mellitus. Cardiology 2008; 109: 99-104
• 19 Al-Biltagi MA, Tolba OA, Mawlana W. et al. Resistin and right ventricular function in children with recently diagnosed type-1 diabetes mellitus: a case control study. J Pediatri Endocrinol Metab 2015; 28: 299-308
• 20 Li G, Li Y, Tan XQ. et al. Plasma growth differentiation factor-15 is a potential biomarker for pediatric pulmonary arterial hypertension associated with congenital heart disease. Pediatr Cardiol 2017; 38: 1620-1626
• 21 Hromádka M, Seidlerová J, Suchý D. et al. Myocardial fibrosis detected by magnetic resonance in systemic sclerosis patients - Relationship with biochemical and echocardiography parameters. Int J Cardiol 2017; 249: 448-453
• 22 Kaya F, Arslan D, Vatansev H. et al. Growth-differentiation factor-15 and tissue Doppler imaging in detection of anthracycline-induced cardiomyopathy during therapy of childhood cancers. J Pediatr Hematol Oncol 2016; 38: 107-112
• 23 Raedle-Hurst TM, Koenigstein K, Gruenhage F. et al. Growth differentiation factor 15-an early marker of abnormal function of the Fontan circuit in patients with univentricular hearts. Am Heart J 2010; 160: 1105-1112
• 24 Khan SQ, Ng K, Dhillon O. et al. Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction. Eur Heart J 2009; 30: 1057-1065
• 25 O’Meara E, de Denus S, Rouleau JL. et al. Circulating biomarkers in patients with heart failure and preserved ejection fraction. Curr Heart Fail Rep 2013; 10: 350-358
• 26 Montoro-García S, Hernández-Romero D, Jover E. et al. Growth differentiation factor-15, a novel biomarker related with disease severity in patients with hypertrophic cardiomyopathy. Eur J Intern Med 2012; 23: 169-174
• 27 Berezin AE. Diabetes mellitus related biomarker: The predictive role of growth-differentiation factor-15. Diabetes Metab Syndr 2016; 10: 154-157
• 28 Dominguez-Rodriguez A, Abreu-Gonzalez P, Avanzas P. Usefulness of growth differentiation factor-15 levels to predict diabetic cardiomyopathy in asymptomatic patients with type 2 diabetes mellitus. Am J Cardiol 2014; 114: 890-894